ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

kg of tqb2102 for injection

A development code. Also written as “6.0 mg/kg of TQB2102 for injection” and “7.5 mg/kg of TQB2102 for injection”.

In Sino Biopharmaceutical’s pipeline, HER2双抗ADC. Its studies are mostly in Breast Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 2, since Dec 27, 20231 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 2since Dec 27, 2023Dec 27, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2102, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 27, 2023First study: phase 2 study in Breast NeoplasmsFirst studyNCT06198751 · 104 enrolled · China

TargetBeta

“HER2双抗ADC”the company's pipeline, read by Claude · source

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06198751Breast Neoplasms · China2Active, not recruitingMay 8, 2025104

How it is read

Names in the registry

  • “6.0 mg/kg of TQB2102 for injection”, 1 entry
  • “7.5 mg/kg of TQB2102 for injection”, 1 entry

Codes read as this program: TQB2102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.